Gefitinib Not Yet Recruiting Phase 3 Trials for 2-year Disease-Free Survival Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03203590Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients